The results are quite expected since AZD1480 is known to be a potent, selective JAK2 inhibitor [27], while ruxolitinib is a potent JAK1 and JAK2 inhibitor approved by FDA for treatment of myelofibrosis [30]. The gene discussed is JAK2; the disease is myelofibrosis.